Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update

Sarnaik, A. (Amod); Khushalani, N. (Nikhil); Chesney, J. (Jason); Kluger, H. (Harriet); Curti, B. (Brendan); Lewis, K. (Karl); Medina, T. (Theresa); Thomas, S. (Sajeve); Pavlick, A. (Anna); Whitman, E. (Eric); Martin-Algarra, S. (Salvador); Corrie, P. (Pippa); Hamid, O. (Omid); Lutzky, J. (Jose); Olah, J. (Judit); Weber, J.S. (Jeffrey S.); Larkin, J. (James); Shi, W. (Wen); DiTrapani, K. (Kelly); Qin, H. (Harry); Mirgoli, M. (Mariam); Wu, R. (Renee); Takamura, T. (Toshimi); Fardis, M. (Maria); Kirkwood, J.M. (John M.)

Keywords:

Treatment options
Advanced melanoma
Inhibitors
Cell therapy

Issue Date:

2020

Publisher:

BMJ

ISSN:

2051-1426

Note:

cc-by-nc-nd

Citation:

Sarnaik, A. (Amod); Khushalani, N. (Nikhil); Chesney, J. (Jason); et al. "Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update". Journal for immunotherapy of cancer. 8 (Suppl 1), 2020,

Abstract

Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies such as BRAF/MEK inhibitors (if BRAF-V600E mutated). Adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) has shown antitumor efficacy with durable responses in heavily pretreated melanoma patients. Safety and efficacy of lifileucel, a centrally manufactured cryopreserved autologous TIL therapy assessed by both investigator and an independent review committee (IRC), are presented.

URI:

https://hdl.handle.net/10171/66224

DOI:

10.1136/LBA2019.18

Appears in Collections:

DA - CUN - Oncología médica - Artículos de revista

Files in This Item: